



Solenio Therapeutics Announces Presentations at the 2022 European Congress of Endocrinology

May 19, 2022 8:05 PM EDT

REDWOOD CITY, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Solenio") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced presentations at the upcoming 2022 European Congress of Endocrinology (ECE), which is being held May 21-24, 2022, in Milan, Italy.

Details of the presentations are as follows:

2022 European Congress of Endocrinology (ECE)

Title: *DCCR Update*
Format: Presentation at the International Prader-Willi syndrome Meeting 2022 organized by INfoRMEd – PWS (the International Network for Research, Management and Education on adults with PWS) and the European Society of Endocrinology
Presenter: Dr. Evelien Gevers on behalf of the DESTINY PWS Investigators
Date: Saturday, May 21, 2022
Time: 12:10 – 12:30 PM CET

Title: *Long-Term Safety of Diazoxide Choline Extended-Release (DCCR) Tablets in Patients with Prader-Willi Syndrome*
Format: E-Poster -- Programme Code: EP360 / Submission Number 2044
Presenter: Dr. Evelien Gevers on behalf of the DESTINY PWS Investigators

Title: *Comparison of hyperphagia and problem behaviors in participants with Prader-Willi syndrome (PWS) receiving Diazoxide Choline Extended-Release (DCCR) with matched participants in PATH for PWS (PfPWS)*
Format: Poster -- Programme Code: P77 / Submission Number 789
Presenter: Dr. Evelien Gevers on behalf of the DESTINY PWS Investigators and the PATH for PWS Investigators
Date: Sunday, May 22, 2022

The copy of the posters will be available in the Investors section on the Company's website at www.soleno.life after presentation at the meeting.

About Soleno Therapeutics, Inc.

Solenio is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, DCCR, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), is currently being evaluated in an ongoing Phase 3 clinical development program. For more information, please visit www.soleno.life.

Corporate Contact:

Brian Ritchie
LifeSci Advisors, LLC
212-915-2578



Source: Soleno Therapeutics